UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anti-programmed cell death-1 therapy in nonmelanoma skin cancer

British journal of dermatology (1951), 2017-02, Vol.176 (2), p.498-502

2017

Volltextzugriff (PDF)

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion

Annals of oncology, 2011-03, Vol.22 (3), p.524-535

2011

Volltextzugriff (PDF)

Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature

Journal of the European Academy of Dermatology and Venereology, 2015-09, Vol.29 (9), p.1797-1806

2015

Volltextzugriff (PDF)

3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma

European journal of cancer (1990), 2015-09, Vol.51, p.S667-S668

2015

Volltextzugriff (PDF)

Corrigendum to ‘IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy’

Annals of oncology, 2021-10, Vol.32 (10), p.1310

2021

Volltextzugriff (PDF)

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

European journal of cancer (1990), 2015-09, Vol.51, p.S664-S665

2015

Volltextzugriff (PDF)

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

The New England journal of medicine, 2016-11, Vol.375 (19), p.1845-1855

2016

Volltextzugriff (PDF)

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Annals of oncology, 2017-02, Vol.28 (2), p.368-376

2017

Volltextzugriff (PDF)

IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy

Annals of oncology, 2021-06, Vol.32 (6), p.696-697

2021

Volltextzugriff (PDF)

Corrigendum to ‘IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy’: Annals of Oncology 2021; volume 32: 696-697

Annals of oncology, 2021-10, Vol.32 (10), p.1310-1310

2021

Volltextzugriff (PDF)

Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients

British journal of dermatology (1951), 2018-02, Vol.178 (2), p.443-451

2018

Volltextzugriff (PDF)

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

Annals of oncology, 2016-10, Vol.27 (10), p.1940-1946

2016

Volltextzugriff (PDF)

1133P Only early adjuvant radiotherapy, particularly of the tumor bed rather than the lymph node region, improves prognosis in Merkel cell carcinoma: Results from the prospective German MCC registry

Annals of oncology, 2024-09, Vol.35, p.S744-S744

2024

Volltextzugriff (PDF)

Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis

Annals of oncology, 2024-03, Vol.35 (3), p.317-326

2024

Volltextzugriff (PDF)

1126P Prediction of clinical outcome by soluble immune checkpoints and T cell subsets in patients treated with immune checkpoint blockers for metastasized melanoma

Annals of oncology, 2020-09, Vol.31, p.S756-S757

2020

Volltextzugriff (PDF)

1809O TRheuMa registry provides real world data on rheumatic immune-related adverse events

Annals of oncology, 2020-09, Vol.31, p.S1046-S1046

2020

Volltextzugriff (PDF)

Das Melanom: Einführung und besondere Anforderungen für die Radiologie

Radiologe, 2015-02, Vol.55 (2), p.93-98

2015

Volltextzugriff (PDF)

1037P Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors

Annals of oncology, 2023-10, Vol.34, p.S629-S630

2023

Volltextzugriff (PDF)

1087MO A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study

Annals of oncology, 2023-10, Vol.34, p.S654-S655

2023

Volltextzugriff (PDF)

1099P COMBI-EU: Adverse event management of adjuvant dabrafenib plus trametinib (D+T) in patients with BRAF V600-mutant melanoma

Annals of oncology, 2024-09, Vol.35, p.S728-S729

2024

Volltextzugriff (PDF)

1107P Characteristics and quality of life of nine-year survivors from 312 patients with metastatic melanoma treated with pembrolizumab

Annals of oncology, 2024-09, Vol.35, p.S733-S734

2024

Volltextzugriff (PDF)

1124P Adjuvant treatment of patients with stage III melanoma: 4-year follow-up time of multicenter real-world study

Annals of oncology, 2024-09, Vol.35, p.S740-S740

2024

Volltextzugriff (PDF)

1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047

Annals of oncology, 2024-09, Vol.35, p.S723-S724

2024

Volltextzugriff (PDF)

PD‐1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma

British journal of dermatology (1951), 2017-01, Vol.176 (1), p.216-219

2017

Volltextzugriff (PDF)

1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma

Annals of oncology, 2023-10, Vol.34, p.S667-S668

2023

Volltextzugriff (PDF)

1 – 25 von 82

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(82)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(25)
Humans
(21)
Middle Aged
(14)
Oncology
(14)
Female
(12)
Male
(12)
Adult
(11)
Dermatology
(11)
Melanoma
(11)
Aged
(10)
Melanoma - Drug Therapy
(9)
Skin Neoplasms - Drug Therapy
(9)
Aged, 80 And Over
(7)
Immunotherapy
(7)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(5)
Antineoplastic Agents - Therapeutic Use
(5)
Disease-Free Survival
(5)
Melanoma - Mortality
(5)
Metastases
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Anti-programmed cell death-1 therapy in nonmelanoma skin cancer

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion

Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature

3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma

Corrigendum to ‘IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy’

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy

Corrigendum to ‘IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy’: Annals of Oncology 2021; volume 32: 696-697

Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

1133P Only early adjuvant radiotherapy, particularly of the tumor bed rather than the lymph node region, improves prognosis in Merkel cell carcinoma: Results from the prospective German MCC registry

Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis

1126P Prediction of clinical outcome by soluble immune checkpoints and T cell subsets in patients treated with immune checkpoint blockers for metastasized melanoma

1809O TRheuMa registry provides real world data on rheumatic immune-related adverse events

Das Melanom: Einführung und besondere Anforderungen für die Radiologie

1037P Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors

1087MO A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study

1099P COMBI-EU: Adverse event management of adjuvant dabrafenib plus trametinib (D+T) in patients with BRAF V600-mutant melanoma

1107P Characteristics and quality of life of nine-year survivors from 312 patients with metastatic melanoma treated with pembrolizumab

1124P Adjuvant treatment of patients with stage III melanoma: 4-year follow-up time of multicenter real-world study

1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047

PD‐1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma

1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma

Suchergebnisse filtern